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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To determine whether NAVA compared to other forms of triggered ventilation results in reduced rates of BPD or death in newborn
infants, either used as a primary or rescue mode of ventilation. To assess the safety of NAVA by determining if there is a greater risk
of episodes of hypocarbia or hypercarbia, intraventricular haemorrhage, periventricular leukomalacia, or air leaks compared to other
forms of triggered ventilation.
Secondary objectives will be to determine whether any benefits differ by gestational age (term or preterm). In crossover trials, outcomes
include peak pressure requirements, oxygenation index and the work of breathing.
B A C K G R O U N D
Despite improvements in survival rates of preterm infants, there
remains a high incidence of ventilator-related complications. In
particular, the incidence of bronchopulmonary dysplasia (BPD)
has been unchanged over the last two decades (Costeloe 2012).
Various definitions have been used to define BPD. The National
Institute of Child Health and Human Development (NICHD),
National Heart, Lung and Blood Institute (NHLBI) and Office of
Rare Disease Research workshop defined BPD as oxygen depen-
dency at 28 days of life (Jobe 2001). Infants are then further sub-
divided at 36 weeks postmenstrual age (PMA) as to whether they
have mild BPD (no longer oxygen dependent), moderate BPD
(an oxygen requirement less than 30%) or severe BPD (an oxygen
requirement of greater than 30%; or a requirement for continu-
ous positive airways pressure (CPAP) or mechanical ventilation).
Oxygen dependency at 36 weeks’ postmenstrual age (PMA) is also
widely used as a definition of BPD.
BPD has a multifactorial aetiology including oxygen toxicity and
volutrauma. Pneumothorax is another important ventilator-re-
lated complication as it often precedes intracerebral haemorrhage
in prematurely born infants. Pneumothoraces occur in infants
whose respiratory efforts are asynchronous with mechanical infla-
tions as they actively expire (Greenough 1984a). In contrast, in-
fants whose respiratory efforts are synchronous with mechanical
ventilation have improved oxygenation and do not develop pneu-
mothoraces. Synchrony can be achieved by the use of fast rates
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(≥ 60 breaths per minute (bpm)) (Greenough 1986); or patient-
triggered ventilation. A Cochrane review compared methods of
improving synchronisation using fast rates (60 to 120 bpm), high
frequency positive pressure ventilation (HFPPV) or patient-trig-
gered ventilation (either assist control ventilation (ACV) or syn-
chronous intermittent mandatory ventilation (SIMV)) with con-
ventional mechanical ventilation (CMV) (Greenough 2008). The
meta-analysis demonstrated that HFPPV compared to CMV was
associated with a reduction in risk of air leak and patient-triggered
ventilation was associated with a shorter duration of ventilation
compared toCMV, but there was no significant reduction in bron-
chopulmonary dysplasia using either mode to improve synchrony.
During ACV and SIMV, triggering is via either pressure or flow
sensors which determine the initiation of inflation. In the neona-
tal population, with small tidal volumes, high respiratory rates
and often significant leak from uncuffed endotracheal tubes, sen-
sitive triggering can be challenging and hence some of the bene-
fits of triggered ventilation may not materialise. During neurally
adjusted ventilatory assist (NAVA) the electrical activity of the di-
aphragm, detected via electrodes on a modified nasogastric tube,
enables both the start and end of an inflation to be synchronised
with the infant’s respiratory effort. Indeed, using NAVA, respira-
tory support can be tailored throughout to the infant’s respiratory
cycle. Thus, it is likely that NAVA may provide superior support
compared to other forms of triggered ventilation.
In this review, we will evaluate whether there is evidence for short-
and long-term benefits of NAVA over other methods of triggered
ventilation in the neonatal population.
Description of the condition
The majority of neonates breathe during mechanical ventilation.
Asynchrony occurs when the ventilator delivers mechanical sup-
port out of phase with the respiratory efforts of the infant. In
a study of 34 infants undergoing mechanical ventilation, eight
infants who went on to develop pneumothoraces were found to
actively exhale against a ventilator inflation (Greenough 1983).
In a randomised controlled trial preterm ventilated infants with
asynchrony were randomised to paralysis with pancuronium, or
no paralysis. Pneumothoraces developed in all 11 unparalysed in-
fants, but in none of those randomised to paralysis (Greenough
1984b). Asynchrony may predispose to other morbidity. Perlman
1985 found an association between fluctuations in cerebral blood
flowand subsequent development of intraventricular haemorrhage
(IVH). Fluctuations in cerebral blood flow and both the incidence
and severity of IVH were reduced with muscle paralysis (Perlman
1985). Synchronisation of respiratory effort with ventilator infla-
tion reduces asynchrony and is associated with improved oxygena-
tion and carbon dioxide elimination (Donn 2003). Synchronisa-
tion of inspiratory efforts with positive pressure inflations should
therefore result in adequate ventilation using lower inflation pres-
sures and reduce the risk of lung injury by either volutrauma or
hyperoxia.
Description of the intervention
Several modes of triggered ventilation have been used in the neona-
tal population and will be considered in this systematic review.
ACV and SIMV both deliver breaths triggered by the infant’s res-
piratory effort, with the former supporting all breaths that are
greater than the critical trigger level and the latter supporting only
the number of breaths set by the practitioner; (breaths above that
preset number are not supported by positive pressure inflations).
During ACV and SIMV, inflations can be pressure limited or vol-
ume targeted. During volume-targeted ventilation a pre-specified
volume is delivered to the infant regardless of changes in their lung
function. In both modes, the timing of the onset of inflation is
determined by the infant’s inspiratory efforts but inflation is ter-
minated when the set inflation time is reached. Patient-triggered
ventilation has usually relied on flow or pressure changes to trigger
inspiration. The infant must initiate a sufficient change in pressure
or flow to trigger ventilator support, and this may result in a de-
lay in delivering an inflation (trigger delay) increasing the infant’s
work of breathing. In contrast, during pressure support ventilation
(PSV), both the beginning and end of inflation are determined
by the infant’s inspiratory efforts, reducing the likelihood of asyn-
chrony (Dimitriou 1998). During proportional assist ventilation
(PAV) the applied pressure is servo controlled throughout each
spontaneous breath. The applied pressure increases in proportion
to the tidal volume and flow generated by the infant. The fre-
quency, timing and magnitude of lung inflation are controlled by
the infant.
Similarly, NAVA provides respiratory support throughout the in-
fant’s respiratory cycle, but the electrical activity of the diaphragm
is used to ’control’ respiratory support. This technique has been
successfully used in very low birth weight infants weighing as little
as 640 grams (Beck 2009). Diaphragmatic activity is determined
by assessing the electric activity of the diaphragm (EAdi) using
a series of electrodes mounted on a modified nasogastric feeding
tube.
How the intervention might work
Changes in electrical activity in the diaphragm at the beginning of
inspiration precede changes in pressure and flow; hence effective
ventilation could be achieved at lower pressures or volumes. In
addition reduction in asynchrony may result in a lower incidence
of pneumothoraces and intracerebral haemorrhage. Furthermore,
respiratory support through the infant’s respiratory cycle is likely
to be more effective, as demonstrated during PAVwith a reduction
in the oxygenation index (Bhat 2015). NAVAmay, therefore, have
a shorter trigger delay than other modes of triggered ventilation.
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During NAVA, termination of inflation is also controlled by the
EAdi signal and hence asynchrony is less likely to occur. Improved
synchronisation could improve oxygenation and carbon dioxide
clearance.
Why it is important to do this review
Patient-triggered ventilation should reduce respiratory morbid-
ity in neonates by improving synchronisation, but results of ran-
domised controlled trials to date have yielded limited positive re-
sults. NAVA is a more sophisticated form of PTV which has re-
cently been developed for neonates. To our knowledge, there are
no systematic reviews evaluating the use of this modality in the
neonatal population; hence, it is important to assess any benefits
of NAVA compared to other triggered modes.
O B J E C T I V E S
TodeterminewhetherNAVAcompared to other forms of triggered
ventilation results in reduced rates of BPD or death in newborn
infants, either used as a primary or rescue mode of ventilation. To
assess the safety of NAVA by determining if there is a greater risk
of episodes of hypocarbia or hypercarbia, intraventricular haemor-
rhage, periventricular leukomalacia, or air leaks compared to other
forms of triggered ventilation.
Secondary objectives will be to determine whether any benefits
differ by gestational age (term or preterm). In crossover trials,
outcomes include peak pressure requirements, oxygenation index
and the work of breathing.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised and quasi-randomised (but not clus-
ter-randomised) controlled studies. For randomised controlled
studies evaluating NAVA as the primary mode of ventilation, ran-
domisation must occur within 24 hours of birth.
Cross-over studies will also be considered, if they have occurred
in the first two weeks after birth and there is a minimum study
period of one hour on each intervention. Studies will be included
even if all outcomes of interest are not reported.
Types of participants
Infants born either at term or preterm requiring mechanical ven-
tilation and studied at a postmenstrual age of less than 44 weeks.
Types of interventions
NAVA - delivered via an endotracheal tube using diaphragmatic
electromyography (EMG) as the trigger device versus other trig-
gered modes:
1) Synchronous intermittent mandatory ventilation (SIMV) (ei-
ther pressure limited or volume targeted)
2) Assist control ventilation (ACV) (either pressure limited or
volume targeted)
3) SIMV or ACV with pressure support or
4) PAV
NAVA will be compared to the ’control’ interventions as:
1) primary mode of ventilation (randomised within 24 hours of
birth)
2) rescue mode (randomised after 24 hours, following any other
mode of ventilation)
Wewill include studies inwhich ventilation is delivered by a trigger
mode; any differences in outcome attributable to trigger mode will
be considered as part of the sub-group analysis.
Types of outcome measures
Primary outcomes
• All-cause mortality
• Bronchopulmonary dysplasia as defined as an oxygen
requirement at 36 weeks’ postmenstrual age for infants of less
than 32 weeks’ gestational age and at 28 days for more mature
infants.
• All-cause mortality or bronchopulmonary dysplasia as
previously defined
Secondary outcomes
• Duration of mechanical ventilation (days)
• Incidence of air leak: pneumothorax or pulmonary
interstitial emphysema (PIE) (author defined)
• Incidence of intracerebral haemorrhage or periventricular
leukomalacia
• Survival with an oxygen requirement at 36 weeks’
postmenstrual age
Outcomes of cross-over trials assessed during each of the study
periods:
• Maximum FiO (fraction of inspired oxygen)
• Mean peak inspiratory pressures (cmH O)
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• Episodes of hypocarbia (pCO < 35 mmHg) defined as
any episode during the study period
• Episodes of hypercarbia (PaCO > 60 mmHg) defined as
any episode during the study period
At the end of each period on each comparator ventilation modes:
• Work of breathing (transdiaphragmatic pressure time
product/cmH O.seconds/minute)
• Oxygenation index ((FiO × mean airway pressure)/
PaO )
• Thoraco-abdominal asynchrony using respiratory
inductance bands (phase angle/degrees)
Search methods for identification of studies
The standard search strategy of theCochrane Neonatal Group will
be used.
Electronic searches
We will search the Cochrane Central Register of Controlled Trials
(CENTRAL, The Cohrane Library);MEDLINE via Ovid SP (Jan-
uary 1966 to date); EMBASE via Ovid SP (January 1980 to date);
CINAHL via EBSCO Host (1982 to date); and Web of Science
(1985 to date). In addition, wewill search abstracts of the Pediatric
Academic Societies Annual Meetings (PAS) (2000 to current); the
Meetings of the European Society of Pediatric Research published
in Pediatric Research; and the Meetings of the Perinatal Society
of Australia and New Zealand (PSANZ) (2005 to current). We
will use the Cochrane Highly Sensitive Search Strategy for iden-
tifying randomised controlled trials as suggested in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We will use the MeSH heading: infant, newborn AND Interac-
tive Ventilatory Support AND the text word “neurally adjusted”
or “NAVA”. A second search will be performed using the MeSH
heading: infant, newborn AND text word “neurally adjusted” OR
“NAVA”. The results of the two searches will be combined. There
will be no restriction on date, language or publications to our
searches.
Searching other resources
In addition we will search the following registries:
• http://www.controlled-trials.com
• http://clinicaltrials.gov
• http://www.anzctr.org.au/
We will check the reference lists of all identified studies for further
relevant studies. We will search conference abstracts for relevant
unpublished studies.
Data collection and analysis
Selection of studies
Three review authors (AG,TR, SS) will undertake the study selec-
tion process. Two authors (TR, SS) will independently identify the
studies and assess whether inclusion criteria are fulfilled. Where
there is disagreement, this will be resolved by consultation with
AG.
The details of all excluded studies will be listed with reason for
exclusion in the table ’Characteristics of excluded studies’.
Data extraction and management
Two review authors (TR, SS) will independently perform data
extraction using a standardised form. Where there is discrepancy
between the two authors this will be resolved by discussion and,
when necessary, consultation with AG.
Assessment of risk of bias in included studies
Risk of bias will be independently assessed by two reviewers (TR,
SS) using the Cochrane’s domain-based tool for assessing risk of
bias. Selectionbias, performance bias, detectionbias, attrition bias,
reporting bias and other bias will be scored. An overall risk of
bias for each study will be ’high risk of bias’, ’low risk of bias’
or ’unclear risk of bias’. This will be made according to guidance
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011). Any disagreements will be resolved by consensus
or, when necessary, discussion with AG.
The following risk of bias domains will be assessed:
1) Selection bias:
a) random sequence generation;
• Low risk: adequate (any truly random process e.g. random
number table; computer random number generator)
• High risk: inadequate (any non-random process e.g. odd or
even date of birth; hospital or clinic record number; allocation by
availability of intervention)
• Unclear risk: no or unclear information provided
b) allocation concealment;
• Low risk: adequate (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes)
• High risk: inadequate (open random allocation; unsealed or
non-opaque envelopes; alternation; date of birth; case record
number)
• Unclear risk: no or unclear information provided
2) Perfomance bias:
a) blinding of participants and personnel;
• Low risk: adequate (blinding ensured and unlikely to have
been broken; no or incomplete blinding but unlikely to have
influenced outcome)
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• High risk: inadequate (blinding attempted but likely that it
could have been broken and influenced outcome; no or
incomplete blinding that is likely to have influenced outcome)
• Unclear risk: no or unclear information provided
3) Detection bias:
a) blinding of outcome assessment;
• Low risk: adequate (blinding of outcome assessment
ensured and unlikely to have been broken; no or incomplete
blinding but unlikely to have influenced outcome)
• High risk: inadequate (blinding of outcome assessment
attempted but likely that it could have been broken and
influenced outcome; no or incomplete blinding that is likely to
have influenced outcome)
• Unclear risk: no or unclear information provided
4) Attrition bias:
a) incomplete outcome data;
• Low risk: adequate (no missing outcome data; reasons for
missing data unlikely to be related to true outcome; missing
outcome data balanced across groups; missing data insufficient to
have a clinically relevant impact on effect estimate or size;
missing data imputed using appropriate methods)
• High risk: inadequate (reason for missing outcome data
likely to be related to true outcome; missing data sufficient to
have a clinically relevant impact on effect estimate or size; ‘as-
treated’ analysis done with substantial departure from
randomised allocation)
• Unclear risk: no or unclear information provided
5) Reporting bias:
a) selective reporting;
• Low risk: adequate (the study protocol is available and all of
the study’s pre-specified primary and secondary outcomes that
are of interest to the review are reported in the pre-specified way;
the protocol is not available but it is clear the published reports
include all expected outcomes)
• High risk: inadequate (not all pre-specified outcomes
reported; one or more primary outcomes is reported using
measurements, analysis, methods or subsets that were not pre-
specified; one or more primary outcomes were not pre-specified;
one or more outcomes of interest are incompletely reported so
that they cannot be entered in meta-analysis; the study fails to
report a key outcome that would have been expected to be
reported)
• Unclear risk: no or unclear information provided
6) other sources of bias.
• Low risk: the study appears free of other sources of bias
• High risk: at least one important risk of bias (related to
study design; study has been claimed to be fraudulent)
• Unclear risk: no or unclear information provided
Data entry into the Review Manager software (Review Manager
(RevMan)) will be undertaken by one author (TR) and verified by
a second author (SS).
Quality of evidence
We will assess the quality of evidence for the main comparison at
the outcome level using the Grading of Recommendations Assess-
ment, Development and Evaluation (GRADE) approach (Guyatt
2011a). This methodological approach considers evidence from
randomised controlled trials as high quality that may be down-
graded based on consideration of any of five areas: design (risk of
bias); consistency across studies; directness of the evidence; preci-
sion of estimates; and presence of publication bias (Guyatt 2011a).
The GRADE approach results in an assessment of the quality of
a body of evidence in one of four grades: “1) High: We are very
confident that the true effect lies close to that of the estimate of
the effect; 2) Moderate: We are moderately confident in the effect
estimate: The true effect is likely to be close to the estimate of
the effect, but there is a possibility that it is substantially differ-
ent; 3) Low: Our confidence in the effect estimate is limited: The
true effect may be substantially different from the estimate of the
effect; 4) Very Low: We have very little confidence in the effect
estimate: The true effect is likely to be substantially different from
the estimate of effect” (Schünemann 2013).
The review authors will independently assess the quality of the
evidence found for outcomes identified as critical or important
for clinical decision making. The critical outcome measures to be
included in the summary of findings are: all-cause mortality or
BPD as previously defined.
In cases where we consider the risk of bias arising from inade-
quate concealment of allocation, inadequately randomised assign-
ment, incomplete follow-up or inadequately blinded outcome as-
sessment reduces our confidence in the effect estimates, we will
downgrade the quality of evidence accordingly (Guyatt 2011b).
Consistency will be evaluated by similarity of point estimates, ex-
tent of overlap of confidence intervals (CIs) and statistical crite-
ria including measurement of heterogeneity (I²). The quality of
evidence will be downgraded when inconsistency across results of
studies was present, large and unexplained (i.e. some studies sug-
gest important benefit and others no effect or harmwithout a clin-
ical explanation) (Guyatt 2011d). Precision will be assessed taking
into account the 95% CI around the pooled estimation (Guyatt
2011c). When trials were conducted in populations other than
the target population, we will downgrade the quality of evidence
because of indirectness (Guyatt 2011e).
We will enter data (i.e. pooled estimates of the effects and corre-
sponding 95% CI) and explicit judgements for each of the aspects
assessed above into theGuidelineDevelopmentTool (GRADEpro
2008), the software used to create ’Summary of findings’ (SoF)
tables. We will explain all judgements involving the assessment of
the study characteristics described above in footnotes or comments
in the SoF table.
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Measures of treatment effect
We will extract categorical data for each intervention group and
calculate the risk ratio (RR) and risk difference (RD). If the risk
difference is statistically significant, we will calculate the number
needed to treat for an additional beneficial outcome or for an
additional harmful outcome.
Analysis of cross-over trials will depend on the risk of carry-over or
period effects. When these are not considered a problem then an
effect estimate will be calculated using the generic inverse variance
method in RevMan (Higgins 2011). Where there are insufficient
data to include a paired analysis in a meta-analysis, data will be
treated as two parallel arms, acknowledging the loss of statistical
power.
Unit of analysis issues
Where insufficient data are available from cross-over trials to in-
corporate paired data in a meta-analysis, we will consider the mea-
surements from each arm separately, as if from a parallel group
trial. As this can result in a unit of analysis error, we will only
include the results if they are demonstrably similar to the results
of a paired analysis (Higgins 2011).
Dealing with missing data
We will contact the authors when we detect that data appear to be
missing. If data are missing from one period of a cross-over trial,
we will exclude data from both periods from analysis.
Assessment of heterogeneity
Heterogeneity will be quantified with the I² statistic calculated
as described in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011). The thresholds for interpreting I²
will be:
• 0% to 25%: no heterogeneity
• 25% to 49%: low heterogeneity
• 40% to 74%: moderate heterogeneity
• ≥ 75%: high heterogeneity
Where I² exceeds 75% we will conduct a sensitivity analysis to
explain the source of heterogeneity.
Assessment of reporting biases
If there are at least 10 trials included in a meta-analysis a funnel
plot will be performed to assess publication bias.
Data synthesis
Meta-analysis will be performed using RevMan and a fixed-effect
model if there are two or more RCTs with comparable popula-
tions and treatment interventions. The RCTs will be considered
comparable if NAVA is used as the primary mode of ventilation
or in a discreet analysis as rescue mode.
We will present our results with 95% CIs. Where different scales
are used to measure the same continuous data between trials the
standardised mean differences (SMDs) will be calculated. For con-
tinuous data themean and standard deviationwill be extracted and
analysis performed using the weighted mean differences (WMD).
Where the outcomes are measured using differing scales the stan-
dardised mean difference will be used.
Wewill assessWMDs, RRs andRDs.The outcomes of comparable
trials will be analysed with 95% CIs to estimate treatment effect.
We will compare results using forest plots, with the RR as the
point estimate for dichotomous outcomes andWMD as the point
estimate for continuous outcomes.
Subgroup analysis and investigation of heterogeneity
Subgroup analysis will be performed according to:
• Gestational age category: either term (≥ 37 weeks of
gestational age) or preterm (< 37 weeks of gestational age)
• Type of triggered ventilation: ACV, SIMV or ACV, SIMV +
PSV, PAV
Sensitivity analysis
If there are sufficient studies we will perform a sensitivity analysis
to evaluate the robustness of the results, and investigate any source
of heterogeneity. Sensitivity analysis may be performed by sepa-
rating studies according to risk of bias in each of the previously
specified domains. A sensitivity analysis may be used particularly
in evaluating data from cross-over studies, determining the effect
of including both study periods.
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